Howard J. Jacob to Deliver Daniel T. O’Connor Memorial Lecture February 23

Dr. Howard J. Jacob will present the Daniel T. O’Connor 2nd Annual Memorial Lecture on Thursday, February 23, 2017, at UC San Diego School of Medicine. His topic is “From Hypertension to Genomic Medicine.”

Dr. Jacob’s lecture will take place in the Leichtag Auditorium (Room 107), with a reception immediately following on the patio.

Dr. Jacob is Executive Vice President for Medical Genomics, Chief Medical Genomics Officer, and Faculty Investigator at HudsonAlpha Institute for Biotechnology. His UC San Diego hosts are Bruce A. Hamilton, PhD, and Nicholas J. Schork, PhD.

Dr. Hamilton is Professor, Cellular and Molecular Medicine, Department of Medicine; Director, Genetics Training Program; and Associate Director, Institute for Genomic Medicine. Dr. Schork is UC San Diego Adjunct Professor, Psychiatry, Family and Preventive Medicine and Director of Human Biology, J. Craig Venter Institute.

The lecture is presented in conjunction with the UC San Diego CTRI Seminar Series and the Genetics, Bioinformatics and Systems Biology Colloquium Series.

Take the 2017 UC San Diego Student Satisfaction Survey

The 2017 Student Satisfaction Survey opens on January 11th and continues until February 17th. Upon completion of the survey, students will automatically receive an exclusive coupon to the UCSD Bookstore and be entered into a raffle for a $400 Visa gift card or one of two swag baskets (includes Fitbit, Hydro Flask, Polaroid, and more)! To participate in the survey, please visit studentsat.ucsd.edu and contact studentsat@ucsd.edu with questions or concerns.

2017 Student Satisfaction Survey Flyer.

2017 Student Satisfaction Survey Flyer.

Researchers Identify New Drug Target for Gastrointestinal Stromal Tumors

In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, with 5,000 to 6,000 new cases per year in the United States.

But 10 to 15 percent of adult GIST cases and most pediatric cases lack the documented tell-tale mutations, making identification and treatment more difficult. In their paper published online Dec. 14 in the Journal of Translational Medicine, researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified new gene fusions and mutations associated with this subset of GIST patients. … Read the Full Story from the UC San Diego Newsroom


Dr. Razelle Kurzrock

Dr. Razelle Kurzrock

The study authors included a number of faculty researchers in the Division of Hematology-Oncology, Department of Medicine, at Moores Cancer Center, including Razelle Kurzrock, MD, Chief, Division of Hematology-Oncology; Murray Professor of Medicine; Senior Deputy Director, Clinical Science; and Director, Center for Personalized Cancer Therapy & Clinical Trials Office.

The other Hematology-Oncology investigators from UC San Diego included Drs. T. Fanta, Martina de Siena, Gregory Heestand, and Olivier Herismendy.

Unexpected Activity of Two Enzymes Helps Explain Why Liver Cancer Drugs Fail

Overturning previous assumptions, study also provides new, more realistic model for liver cancer research and drug development —

Some cancers are caused by loss of enzymes that should keep cell growth in check. On the flip side, some are caused by over-activation of enzymes that enhance cell growth. Yet drugs that inhibit the overactive enzymes have failed to work against liver cancer. In mouse models, researchers at University of California San Diego School of Medicine have discovered a potential reason — counterintuitively, lack of both types of these enzymes can lead to liver disease and cancer. In human liver tumor samples, they also found that deficiencies in these two enzymes, called Shp2 and Pten, are associated with poor prognosis.

The study, published December 13 by Cell Reports, provides a new understanding of how liver cancer develops, a new therapeutic approach and new mouse model for studying the disease. … Read the Full Story from the UC San Diego Newsroom


Rohit Loomba, MD

Rohit Loomba, MD

The study team includes Rohit Loomba, MD, MHSc, Director of the NAFLD Research Center and Director of Hepatology in the Division of Gastroenterology, Department of Medicine at UC San Diego. Dr. Loomba is Professor of Medicine (with tenure) and Vice Chief, Division of Gastroenterology.

Dr. Loomba is also Adjunct Professor, Division of Epidemiology, Department of Family Medicine and Public Health.

New UC San Diego Program Expands Campus Innovation Pipeline

The innovation ecosystem at UC San Diego will open more opportunities for campus entrepreneurs with the launch of Accelerating Innovations to Market (AIM), an ambitious program that encourages graduate students, postdoctoral scholars, researchers and faculty to develop and commercialize their problem-solving ideas.

Coordinated by the Office of Innovation and Commercialization (OIC), the program invests in milestone-based projects that develop proofs-of-concept and reduce the risk of early-stage technologies. According to Paul Roben, Associate Vice Chancellor for Innovation, a central focus of AIM is value-driven engagement with industry. … Read the Full Story from the UC San Diego Newsroom

Creating Clinical Bioengineers

New class teaches undergrads to use engineering-based solutions to bridge gap between engineering and medicine —

A group of UC San Diego bioengineering students huddle around a computer screen as colored images of blood being pumped through a heart flash across the screen. The students are observing as a physician annotates an MRI of a patient’s heart and recommend treatment.

“It looks like there is fat here where there shouldn’t be,” says the physician as he pointed to a spot on the screen. “See how this part of the heart isn’t contracting?” … Read the Full Story from the UC San Diego Newsroom


The Division of Cardiology in the Department of Medicine is one of the rotation sites in the Clinical Bioengineering class.

Protein That Protects During Stress Sheds Light on How Diabetes Drug Prevents Tumors

Researchers at University of California San Diego School of Medicine have identified a previously unknown mechanism that helps fortify the structure and tight junctions between epithelial cells — a basic cell type that lines various body cavities and organs throughout the body, forming a protective barrier against toxins, pathogens and inflammatory triggers. Breaches of this barrier can provoke organ dysfunction and development of tumors.

The findings, published online in the current issue of eLife by senior author Pradipta Ghosh, MD … Read the Full Story from the UC San Diego Newsroom


Dr. Pradipta Ghosh

Pradipta Ghosh, MD

Pradipta Ghosh, MD, MBBS, is Professor of Medicine in the Division of Gastroenterology.

She is a graduate of the UC San Diego Internal Medicine Residency Training Program, the Gastroenterology Fellowship Training Program and the Department of Medicine Physician-Scientist Training Program.

New Bioinformatic Analysis Reveals Role of Proteins in Diabetic Kidney Disease

MDM2 emerges as key; Software could expose metabolomic information of other diseases —

A new bioinformatic framework developed by researchers at University of California San Diego School of Medicine has identified key proteins significantly altered at the gene-expression level in biopsied tissue from patients with diabetic kidney disease, a result that may reveal new therapeutic targets. … Read the Full Story from the UC San Diego Newsroom


Kumar Sharma, MD, FAHADr. Kumar Sharma is lead investigator of the team that published the study report in JCI Insights.Kumar Sharma, MD, is Professor of Medicine in the Division of Nephrology and Hypertension.

He directs the Institute for Metabolomic Medicine and the Center for Renal Translational Medicine at UC San Diego School of Medicine.

Study Report (full text UC San Diego only)

Study Finds Psoriasis Drug Significantly Effective in Treating Crohn’s Disease

Researchers at University of California San Diego School of Medicine have shown that ustekinumab, a human antibody used to treat arthritis, significantly induces response and remission in patients with moderate to severe Crohn’s disease. Results of the clinical trial will appear in the November 16 issue of the New England Journal of Medicine.

“A high percentage of the patients in the study who had not responded to conventional therapies were in clinical remission after only a single dose of intravenous ustekinumab,” said William J. Sandborn, MD, professor of medicine at UC San Diego School of Medicine and director of the Inflammatory Bowel Disease Center at UC San Diego Health. … Read the Full Story from the UC San Diego Newsroom


Dr. William Sandborn

William J. Sandborn, MD

William A. Sandborn, MD, is chief of the Division of Gastroenterology in the Department of Medicine.

Insulin Resistance Reversed by Removal of Protein

By removing the protein galectin-3 (Gal3), a team of investigators led by University of California School of Medicine researchers were able to reverse diabetic insulin resistance and glucose intolerance in mouse models of obesity and diabetes. … Read the Full Story from the UC San Diego Newsroom


Dr. Jerrold Olefsky

Dr. Jerrold Olefsky

Dr. Jerrold Olefsky, Professor of Medicine in the Division of Endocrinology and Metabolism in the School of Medicine at UC San Diego, is principal investigator of this international study.

Read the Study Report (Full Content, UCSD Only)

See Dr. Olefsky’s Research Profile